Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katharina Nickel

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
MMW Fortschritte Der Medizin|January 17, 2023
[Important developments in the therapy of AML]Katharina Nickel
Oncology Research and Treatment|November 8, 2021
Multiple Myeloma: Molecular Pathogenesis and Disease EvolutionMichael Heider, Katharina Nickel, Marion Högner, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 5, 2019
Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysisMarc Botteman, Katharina Nickel, Shelby Corman, et al.
BMC Infectious Diseases|February 27, 2021
Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysisKatharina Nickel, Nicholas J A Halfpenny, Sonya J Snedecor, et al.
BMC Infectious Diseases|April 13, 2021
Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysisKatharina Nickel, Nicholas J A Halfpenny, Sonya J Snedecor, et al.
Leukemia Research|March 6, 2020
Management of patients with acute lymphoblastic leukemia in routine clinical practice: Minimal residual disease testing, treatment patterns and clinical outcomes in Belgium, Greece and SwitzerlandDries Deeren, Stefan Balabanov, Katharina Nickel, et al.
Cancer Medicine|July 2, 2020
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myelomaXiang Zhou, Maximilian J Steinhardt, Denise Grathwohl, et al.
Journal of Comparative Effectiveness Research|July 11, 2023
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinomaSvenja Petersohn, Bradley McGregor, Sven L Klijn, et al.
Cancers|April 29, 2020
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary DiseaseXiang Zhou, Patricia Flüchter, Katharina Nickel, et al.
European Journal of Haematology|January 11, 2020
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphomaXiang Zhou, Maximilian Johannes Steinhardt, Johannes Düll, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
MMW Fortschritte Der Medizin|January 17, 2023
[Important developments in the therapy of AML]Katharina Nickel
Oncology Research and Treatment|November 8, 2021
Multiple Myeloma: Molecular Pathogenesis and Disease EvolutionMichael Heider, Katharina Nickel, Marion Högner, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 5, 2019
Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysisMarc Botteman, Katharina Nickel, Shelby Corman, et al.
BMC Infectious Diseases|February 27, 2021
Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysisKatharina Nickel, Nicholas J A Halfpenny, Sonya J Snedecor, et al.
BMC Infectious Diseases|April 13, 2021
Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysisKatharina Nickel, Nicholas J A Halfpenny, Sonya J Snedecor, et al.
Leukemia Research|March 6, 2020
Management of patients with acute lymphoblastic leukemia in routine clinical practice: Minimal residual disease testing, treatment patterns and clinical outcomes in Belgium, Greece and SwitzerlandDries Deeren, Stefan Balabanov, Katharina Nickel, et al.
Cancer Medicine|July 2, 2020
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myelomaXiang Zhou, Maximilian J Steinhardt, Denise Grathwohl, et al.
Journal of Comparative Effectiveness Research|July 11, 2023
Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinomaSvenja Petersohn, Bradley McGregor, Sven L Klijn, et al.
Cancers|April 29, 2020
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary DiseaseXiang Zhou, Patricia Flüchter, Katharina Nickel, et al.
European Journal of Haematology|January 11, 2020
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphomaXiang Zhou, Maximilian Johannes Steinhardt, Johannes Düll, et al.
Pageof 2